RxDoctor Payments Data

Pauline Bland, OD

Optometrist · Clinton, IANPI 1184009847

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (39.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Glaukos Corporation at 39.9% of the total. Reporting peaked in 2020 at $1,690 and has fallen 97.9% since, to $36 in 2025. Among optometrist clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,756in general payments, 2019–2025

Across 52 payments — averaging $72.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$2K
  • Johnson & Johnson Surgical Vision, Inc.$1K
  • Alcon$312
  • Quidel Corporation$297
  • AbbVie$151
  • Oyster Point Pharma, Inc.$79
  • plus $215 from 9 others

What the payments were for

  • Consulting fees$1,50040%
  • Travel & lodging$1,01527%
  • Food & beverage$1,22133%
  • Gifts$191%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,756 in reported general payments places this provider in the 95th percentile of 559 optometrist providers in Iowa.

See all optometrist providers in Iowa

Medicare billing

Part B allowed, 2024
$121,666
Medicare patients
639
Services billed
1,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine78$88,193
XiidraLifitegrast20$30,745
Cyclosporine25$8,170
Loteprednol Etabonate27$4,491
Fluorometholone25$2,502
Prednisolone Acetate31$1,485
Latanoprost121$890
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat42$593
Dexamethasone Sodium Phosphate14$521
Doxycycline Hyclate12$184
Timolol Maleate24$62

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$151$88,19378 claims
Bausch & Lomb Americas Inc.Xiidra$14$30,74520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 559 optometrist providers in Iowa.

Other optometrist in Clinton

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →